DK2452189T3 - Fremgangsmåde til identifikation af forbindelser til behandling af cancer - Google Patents

Fremgangsmåde til identifikation af forbindelser til behandling af cancer

Info

Publication number
DK2452189T3
DK2452189T3 DK10730456.0T DK10730456T DK2452189T3 DK 2452189 T3 DK2452189 T3 DK 2452189T3 DK 10730456 T DK10730456 T DK 10730456T DK 2452189 T3 DK2452189 T3 DK 2452189T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
identifying compounds
identifying
compounds
Prior art date
Application number
DK10730456.0T
Other languages
English (en)
Inventor
Gonzalez Maria Soledad Soengas
Carulla Damia Tormo
Original Assignee
Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii filed Critical Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii
Application granted granted Critical
Publication of DK2452189T3 publication Critical patent/DK2452189T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
DK10730456.0T 2009-07-04 2010-07-05 Fremgangsmåde til identifikation af forbindelser til behandling af cancer DK2452189T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930417A ES2368963B1 (es) 2009-07-04 2009-07-04 Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado.
PCT/EP2010/059593 WO2011003883A1 (en) 2009-07-04 2010-07-05 Process for the identification of compounds for treating cancer

Publications (1)

Publication Number Publication Date
DK2452189T3 true DK2452189T3 (da) 2014-01-20

Family

ID=42556459

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10730456.0T DK2452189T3 (da) 2009-07-04 2010-07-05 Fremgangsmåde til identifikation af forbindelser til behandling af cancer

Country Status (18)

Country Link
US (5) US20120172581A1 (da)
EP (1) EP2452189B1 (da)
JP (2) JP5908398B2 (da)
KR (1) KR101877840B1 (da)
CN (3) CN102483404A (da)
AU (1) AU2010270291B2 (da)
BR (1) BR112012000098B1 (da)
CA (1) CA2767148C (da)
DK (1) DK2452189T3 (da)
ES (2) ES2368963B1 (da)
IL (1) IL217310A (da)
MX (1) MX2012000280A (da)
NZ (1) NZ597793A (da)
PL (1) PL2452189T3 (da)
PT (1) PT2452189E (da)
SG (1) SG177482A1 (da)
WO (1) WO2011003883A1 (da)
ZA (1) ZA201200116B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154944A2 (en) * 2011-05-10 2012-11-15 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
US10278991B2 (en) 2014-05-14 2019-05-07 Targimmune Therapeutics Ag Polyethyleneimine polyethyleneglycol vectors
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
PT3319587T (pt) 2015-11-17 2019-11-20 Bioncotech Therapeutics S L Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina
CN107198777A (zh) * 2016-04-01 2017-09-26 依生生物制药(新加坡)私人有限公司 用于治疗癌症的含有聚核苷酸的药物组合物
JP2020520368A (ja) * 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ.エレ 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
CN109200056A (zh) * 2018-11-20 2019-01-15 苏州系统医学研究所 聚肌胞在防治胰腺炎及其相关病症中的用途
CN113164386A (zh) 2018-11-21 2021-07-23 亮点医疗有限责任公司 纳米复合聚(i:c)制剂及其用途
WO2021104442A1 (en) * 2019-11-27 2021-06-03 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
CN111166769B (zh) * 2020-03-18 2022-01-11 山东大学 真皮成纤维细胞在治疗黑色素瘤中的应用
CN116685315A (zh) * 2020-06-15 2023-09-01 代谢科技有限责任公司 β-羟基-β-甲基丁酸(HMB)和化疗剂的组合物和使用方法
WO2022111829A1 (en) 2020-11-30 2022-06-02 Symrise Ag Essential oils of citrus fruits for use as medicament for induced, increased and/or accelerated autophagy in human keratinocytes
CN113413460A (zh) * 2021-08-10 2021-09-21 中山大学·深圳 Traf6抑制剂在制备黑色素瘤药物中的应用
KR102747085B1 (ko) * 2022-09-16 2024-12-27 재단법인 아산사회복지재단 자가포식 조절제를 스크리닝하는 방법
WO2025202219A1 (en) * 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Mda5 inhibition as a broad defense and healthspan extending strategy
CN119925643B (zh) * 2025-01-23 2026-06-30 中国科学院生物物理研究所 提高lsh含量或活性的物质在提高异染色质稳定性与增强细胞治疗疗效中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4124702A (en) * 1971-07-06 1978-11-07 Merck & Co., Inc. Polynucleotides active as inducers of interferon production in living animal cells
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
US7229822B1 (en) * 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
CA2475928A1 (en) * 2002-02-14 2003-08-21 Research Development Foundation Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
WO2004045491A2 (en) * 2002-11-18 2004-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted double stranded rna mediated cell killing
CA2548992A1 (en) * 2003-12-11 2005-08-11 Vaxdesign Corporation Immunotherapy compositions, method of making and method of use thereof
US20080220416A1 (en) * 2004-05-20 2008-09-11 The Board Of Trustees Of The University Of Illinoi Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof
EP1774031A2 (en) * 2004-05-26 2007-04-18 Wisconsin Alumni Research Foundation Cancer treatment method by inhibiting mage gene expression or function
WO2006119619A1 (en) * 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
CN101182517A (zh) * 2007-12-18 2008-05-21 广州拓谱基因技术有限公司 用于疾病治疗的多靶点鸡尾酒双链小干扰rna及其制备方法

Also Published As

Publication number Publication date
JP5908398B2 (ja) 2016-04-26
JP6222749B2 (ja) 2017-11-01
CN104857016A (zh) 2015-08-26
BR112012000098B1 (pt) 2019-03-06
US20120172581A1 (en) 2012-07-05
EP2452189B1 (en) 2013-10-16
MX2012000280A (es) 2012-12-05
CN104857016B (zh) 2019-12-24
ZA201200116B (en) 2012-09-26
US20190117685A1 (en) 2019-04-25
PT2452189E (pt) 2014-01-22
KR20120055550A (ko) 2012-05-31
ES2368963A1 (es) 2011-11-24
US20140154202A1 (en) 2014-06-05
KR101877840B1 (ko) 2018-08-09
US20190134077A1 (en) 2019-05-09
AU2010270291A1 (en) 2012-02-16
ES2368963B1 (es) 2012-10-10
IL217310A0 (en) 2012-02-29
JP2016104744A (ja) 2016-06-09
BR112012000098A2 (pt) 2014-10-07
US20170020917A1 (en) 2017-01-26
JP2012531193A (ja) 2012-12-10
IL217310A (en) 2017-05-29
WO2011003883A1 (en) 2011-01-13
PL2452189T3 (pl) 2014-05-30
SG177482A1 (en) 2012-02-28
CN110974842A (zh) 2020-04-10
NZ597793A (en) 2013-05-31
CA2767148C (en) 2019-05-28
CN102483404A (zh) 2012-05-30
EP2452189A1 (en) 2012-05-16
RU2012103902A (ru) 2013-08-20
CA2767148A1 (en) 2011-01-13
ES2442623T3 (es) 2014-02-12
CN110974842B (zh) 2023-09-19
AU2010270291B2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
DK3289876T3 (da) Forbindelser til behandling af cancer
DK3329775T3 (da) Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser
DK2325648T3 (da) Fremgangsmåde til detektering af cancer
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
DK2440545T3 (da) Forbindelser, der er anvendelige til behandling af cancer
BRPI0810206A2 (pt) Método de tratar câncer
DK2504451T3 (da) Fremgangsmåder til at forudsige det kliniske forløb af cancer
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
IL232222A0 (en) Methods for treating progressive multiple sclerosis
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
BRPI1013317A2 (pt) método de cimentação
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
DK2076540T3 (da) Hidtil ukendte anti-cd38-antistoffer til behandling af cancer
DK3106873T3 (da) Fremgangsmåde til detektering af cancer
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
LT2313364T (lt) Simetrinio dimetilarginino nustatymo būdai
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK3276004T3 (da) Fremgangsmåder til behandling af kronisk nyresygdom
BR112012000098A2 (pt) Processo para identificação de compostos para tratar câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
HUE052219T2 (hu) Eljárás kinolon vegyületek elõállítására